EUVIMEDEUVIMED entdecken
Klinische Studie

Switching From ARBs to Sacubitril/Valsartan Safely Improves 24-Hour Ambulatory Blood Pressure in Patients With Advanced Chronic Kidney Disease

Sho Kinguchi, Kohei Ishiga, Hiromichi Wakui, Kengo Azushima, Tomohiko Kanaoka, Yusuke Kobayashi, Tatsuya Haze, Nobuhito Hirawa, Kouichi Tamura iD

American Journal of Hypertension · 2025

DOI: 10.1093/ajh/hpaf028 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift American Journal of Hypertension, 2025. Verfasst von Sho Kinguchi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan. Hauptthemen laut MEDLINE: Aminobutyrates, Angiotensin Receptor Antagonists, Antihypertensive Agents, Blood Pressure. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND We investigated the effects of sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor (ARNI), on 24-hour blood pressure (BP) and safety for 12 weeks in Japanese patients with non-dialysis advanced chronic kidney disease (CKD). METHODS We conducted a prospective, single-arm exploratory study. Patients with non-dialysis CKD stage G4-5 (estimated glomerular filtration (eGFR) <30 mL/min/1.73 m2) who did not achieve their BP goals with angiotensin receptor blocker (ARB) administration, were enrolled and switched to sacubitril/valsartan. Primary and key secondary endpoints were changes from baseline in the 24-hour systolic BP (SBP) measured via ambulatory BP monitoring (ABPM) over 12 weeks and the safety, especially incidence of serum creatinine (Cr) increase (≥ 30% increase from baseline) and hyperkalemia. RESULTS Thirty patients were enrolled, and 29 patients were switched to sacubitril/valsartan. Efficacy analysis was conducted on 26 patients. Baseline mean eGFR and office BP were 21.1 ± 5.0 mL/min/1.73m2 and 149.4 ± 23.7/80.7 ± 11.9 mmHg, respectively. Baseline 24-hour, daytime, and nighttime BP were 139.6 ± 17.7/77.0 ± 7.8 mmHg, 143.5 ± 18.5/79.6 ± 8.7 mmHg, and 131.0 ± 20.4/71.1 ± 8.8 mmHg, respectively. After 12 weeks, changes in 24-hour, daytime, and nighttime SBP from baseline were -7.1 ± 12.4 mmHg (P < 0.01), -7.7 ± 12.9 mmHg (P < 0.01), and -5.8 ± 15.8 mmHg (P = 0.07), respectively. No incidences of potassium values > 6.0 mmol/L or serum Cr ≥ 30% increase from baseline were reported after sacubitril/valsartan initiation. CONCLUSIONS Switching from ARB to sacubitril/valsartan can safely enhance 24-hour antihypertensive treatment in patients with non-dialysis CKD G4-5 who do not achieve BP goals with ARBs. CLINICAL TRIALS REGISTRATION: Trial Number jRCT1031220149. CLINICAL TRIALS REGISTRATION Trial Number jRCT1031220149.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminobutyratesAngiotensin Receptor AntagonistsAntihypertensive AgentsBlood PressureDrug SubstitutionHypertensionRenal Insufficiency, ChronicTetrazolesValsartanAgedFemaleHumansMaleMiddle AgedBiphenyl CompoundsBlood Pressure Monitoring, AmbulatoryDrug CombinationsGlomerular Filtration RateHyperkalemiaJapanNeprilysinProspective StudiesTime FactorsTreatment Outcome

Stichwörter der Autor:innen

ambulatory blood pressure monitoringangiotensin receptor neprilysin inhibitorblood pressurechronic kidney diseasehypertensionsacubitril/valsartan

Substanzen

AminobutyratesAngiotensin Receptor AntagonistsAntihypertensive AgentsBiphenyl CompoundsDrug CombinationsNeprilysinsacubitril and valsartan sodium hydrate drug combinationTetrazolesValsartan

Autor:innen und Institutionen

  • Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Department of Nephrology and Hypertension, Yokohama City University Center Hospital, Yokohama, Japan.
  • YCU Co-Creation Innovation Center, Yokohama City University, Yokohama, Japan.
  • YCU Center for Novel and Exploratory Clinical Trials (Y-NEXT), Yokohama City University Hospital, Yokohama, Japan.

ORCID-Profile: Kouichi Tamura

Zitieren

APA

Kinguchi, S., Ishiga, K., Wakui, H., Azushima, K., Kanaoka, T., Kobayashi, Y., Haze, T., Hirawa, N., & Tamura, K. (2025). Switching From ARBs to Sacubitril/Valsartan Safely Improves 24-Hour Ambulatory Blood Pressure in Patients With Advanced Chronic Kidney Disease. American Journal of Hypertension. https://doi.org/10.1093/ajh/hpaf028

Vancouver

Kinguchi S, Ishiga K, Wakui H, Azushima K, Kanaoka T, Kobayashi Y, et al. Switching From ARBs to Sacubitril/Valsartan Safely Improves 24-Hour Ambulatory Blood Pressure in Patients With Advanced Chronic Kidney Disease. American Journal of Hypertension. 2025. doi:10.1093/ajh/hpaf028

BibTeX
@article{Kinguchi2025,
  author = {Kinguchi, Sho and Ishiga, Kohei and Wakui, Hiromichi and Azushima, Kengo and Kanaoka, Tomohiko and Kobayashi, Yusuke and Haze, Tatsuya and Hirawa, Nobuhito and Tamura, Kouichi},
  title = {Switching From ARBs to Sacubitril/Valsartan Safely Improves 24-Hour Ambulatory Blood Pressure in Patients With Advanced Chronic Kidney Disease},
  journal = {American Journal of Hypertension},
  year = {2025},
  doi = {10.1093/ajh/hpaf028}
}
Kostenlos starten →